GH Research (NASDAQ:GHRS) Trading Up 5.9% - Time to Buy?

GH Research PLC (NASDAQ:GHRS - Get Free Report) shares traded up 5.9% during trading on Tuesday . The company traded as high as $9.67 and last traded at $9.75. 204,153 shares traded hands during trading, an increase of 30% from the average session volume of 156,669 shares. The stock had previously closed at $9.21.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Royal Bank of Canada assumed coverage on GH Research in a research report on Friday. They set an "outperform" rating and a $31.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of GH Research in a research report on Monday, January 27th. Canaccord Genuity Group lowered their price target on GH Research from $31.00 to $28.00 and set a "buy" rating for the company in a research report on Monday, November 18th. Cantor Fitzgerald started coverage on GH Research in a research report on Thursday, February 13th. They issued an "overweight" rating and a $14.00 target price for the company. Finally, Stifel Nicolaus increased their target price on GH Research from $18.00 to $32.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, GH Research presently has a consensus rating of "Buy" and a consensus target price of $30.67.

GH Research Stock Performance

The company has a market cap of $546.29 million, a P/E ratio of -13.29 and a beta of 0.94. The stock has a 50-day moving average of $10.73 and a two-hundred day moving average of $9.20.

Remove Ads

GH Research (NASDAQ:GHRS - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. Research analysts predict that GH Research PLC will post -0.8 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GHRS. Lynx1 Capital Management LP increased its position in GH Research by 15.8% during the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company's stock valued at $34,013,000 after buying an additional 663,100 shares in the last quarter. Diadema Partners LP purchased a new stake in GH Research during the 4th quarter valued at $711,000. RA Capital Management L.P. boosted its stake in GH Research by 1.3% during the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company's stock valued at $44,734,000 after purchasing an additional 85,000 shares during the last quarter. Woodline Partners LP boosted its stake in GH Research by 112.0% during the 4th quarter. Woodline Partners LP now owns 78,949 shares of the company's stock valued at $553,000 after purchasing an additional 41,711 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in GH Research during the 4th quarter valued at $145,000. Institutional investors own 56.90% of the company's stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).